Charles River

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Charles River and other ETFs, options, and stocks.

About CRL

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 

CEO
James C. Foster
CEOJames C. Foster
Employees
20,100
Employees20,100
Headquarters
Wilmington, Massachusetts
HeadquartersWilmington, Massachusetts
Founded
1947
Founded1947
Employees
20,100
Employees20,100

CRL Key Statistics

Market cap
9.50B
Market cap9.50B
Price-Earnings ratio
-124.14
Price-Earnings ratio-124.14
Dividend yield
Dividend yield
Average volume
814.40K
Average volume814.40K
High today
$195.19
High today$195.19
Low today
$192.14
Low today$192.14
Open price
$192.99
Open price$192.99
Volume
446.02K
Volume446.02K
52 Week high
$199.66
52 Week high$199.66
52 Week low
$91.86
52 Week low$91.86

Stock Snapshot

Charles River(CRL) stock is priced at $193.03, giving the company a market capitalization of 9.5B. It carries a P/E multiple of -124.14.

On 2025-12-14, Charles River(CRL) stock traded between a low of $192.14 and a high of $195.19. Shares are currently priced at $193.03, which is +0.5% above the low and -1.1% below the high.

The Charles River(CRL)'s current trading volume is 446.02K, compared to an average daily volume of 814.4K.

In the last year, Charles River(CRL) shares hit a 52-week high of $199.66 and a 52-week low of $91.86.

In the last year, Charles River(CRL) shares hit a 52-week high of $199.66 and a 52-week low of $91.86.

CRL News

Simply Wall St 9h
Assessing Charles River Laboratories Valuation as Its Cell & Gene Therapy Incubator Program Expands

Incubator expansion puts Charles River in focus Charles River Laboratories International (CRL) has kicked off the second cohort of its Cell and Gene Therapy In...

Assessing Charles River Laboratories Valuation as Its Cell & Gene Therapy Incubator Program Expands

Analyst ratings

53%

of 19 ratings
Buy
52.6%
Hold
47.4%
Sell
0%

People also own

Based on the portfolios of people who own CRL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.